Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure

Table 2 Comparison of variables between baseline and 6 months after the administration of dapagliflozin

	Baseline	6 months	p value
Clinical characteristics
Body mass index, kg/m²	25.9 ± 5.1	25.4 ± 5.1	< 0.001
Systolic blood pressure, mmHg	130 ± 16	128 ± 18	0.218
BNP, pg/mL	27.9 (9.0–58.2)	28.9 (9.6–62.9)	0.132
eGFR, mL/min/1.73 m²	70.6 ± 17.0	65.6 ± 15.3	0.001
HbA1c, %	7.2 ± 0.8	7.0 ±0.8	0.108
Echocardiographic parameters
LV end-diastolic volume, mL	74.2 (55.1–104.1)	68.5 (54.8–93.8)	0.270
LV end-systolic volume, mL	24.7 (17.0–54.5)	20.5 (15.2–57.1)	0.105
LVEF, %	62.3 (49.3–68.3)	63.6 (55.3–71.0)	0.011
LVMI, g/m²	75.0 (61.7–92.0)	67.0 (55.0–81.9)	<0.001
LAVI, mL/m²	31 (23–45)	26 (21–32)	0.001
E/e′	9.3 (7.7–11.8)	8.5(6.6–10.7)	0.020

Data are mean ± SD for normally distributed data and median and interquartile range for non-normally distributed data, or n (%)
Abbreviation as in Table 1

ISSN: 1475-2840